Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Improving the quality of cognitive screening assessments: ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-III.

Newman CGJ, Bevins AD, Zajicek JP, Hodges JR, Vuillermoz E, Dickenson JM, Kelly DS, Brown S, Noad RF.

Alzheimers Dement (Amst). 2017 Dec 29;10:182-187. doi: 10.1016/j.dadm.2017.12.003. eCollection 2018.

2.

Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis.

Zeissler ML, Eastwood J, McCorry K, Hanemann CO, Zajicek JP, Carroll CB.

Oncotarget. 2016 Jul 19;7(29):46603-46614. doi: 10.18632/oncotarget.10314.

3.

A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease.

McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE.

BMC Neurol. 2016 Jun 16;16:92. doi: 10.1186/s12883-016-0606-3. Review.

4.

A systematic review of biomarkers for disease progression in Alzheimer's disease.

McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

PLoS One. 2014 Feb 18;9(2):e88854. doi: 10.1371/journal.pone.0088854. eCollection 2014. Review. Erratum in: PLoS One. 2014;9(5):e97960.

5.

A systematic review of biomarkers for disease progression in Parkinson's disease.

McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE.

BMC Neurol. 2013 Apr 12;13:35. doi: 10.1186/1471-2377-13-35. Review.

6.

Can the ABILHAND handle manual ability in MS?

Barrett LE, Cano SJ, Zajicek JP, Hobart JC.

Mult Scler. 2013 May;19(6):806-15. doi: 10.1177/1352458512462919. Epub 2012 Oct 24.

PMID:
23095289
7.

Machine learning-based method for personalized and cost-effective detection of Alzheimer's disease.

Escudero J, Ifeachor E, Zajicek JP, Green C, Shearer J, Pearson S; Alzheimer's Disease Neuroimaging Initiative.

IEEE Trans Biomed Eng. 2013 Jan;60(1):164-8. doi: 10.1109/TBME.2012.2212278. Epub 2012 Aug 8.

PMID:
22893371
8.

Bioprofile analysis: a new approach for the analysis of biomedical data in Alzheimer's disease.

Escudero J, Ifeachor E, Zajicek JP; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2012;32(4):997-1010. doi: 10.3233/JAD-2012-121024.

PMID:
22886027
9.

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group.

J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32. doi: 10.1136/jnnp-2012-302468. Epub 2012 Jul 12.

PMID:
22791906
10.

Machine Learning classification of MRI features of Alzheimer's disease and mild cognitive impairment subjects to reduce the sample size in clinical trials.

Escudero J, Zajicek JP, Ifeachor E; Alzheimer’s Disease Neuroimaging Initiative.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:7957-60. doi: 10.1109/IEMBS.2011.6091962.

PMID:
22256186
11.

Early detection and characterization of Alzheimer's disease in clinical scenarios using Bioprofile concepts and K-means.

Escudero J, Zajicek JP, Ifeachor E.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6470-3. doi: 10.1109/IEMBS.2011.6091597.

PMID:
22255820
12.

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.

PMID:
22236282
13.

Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Shearer J, Green C, Ritchie CW, Zajicek JP.

Drugs Aging. 2012 Jan 1;29(1):31-43. doi: 10.2165/11597380-000000000-00000. Review.

PMID:
22191721
14.

The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.

Hawton A, Green C, Telford CJ, Wright DE, Zajicek JP.

Mult Scler. 2012 Jun;18(6):853-61. doi: 10.1177/1352458511429319. Epub 2011 Nov 22.

PMID:
22108867
15.

Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.

Green C, Shearer J, Ritchie CW, Zajicek JP.

Value Health. 2011 Jul-Aug;14(5):621-30. doi: 10.1016/j.jval.2010.12.008. Review.

16.

The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease.

Shearer J, Green C, Counsell CE, Zajicek JP.

J Neurol. 2012 Mar;259(3):462-8. doi: 10.1007/s00415-011-6202-y. Epub 2011 Aug 5.

PMID:
21818689
17.

The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.

Shearer J, Green C, Counsell CE, Zajicek JP.

Appl Health Econ Health Policy. 2011 Jul 1;9(4):243-58. doi: 10.2165/11590160-000000000-00000. Review.

PMID:
21682352
18.

Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease.

Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE, Hanemann CO.

Neurochem Int. 2011 Aug;59(1):73-80. doi: 10.1016/j.neuint.2011.05.006. Epub 2011 Jun 6.

PMID:
21672570
19.

Designing clinical trials in older people.

Carroll CB, Zajicek JP.

Maturitas. 2011 Apr;68(4):337-41. doi: 10.1016/j.maturitas.2011.02.002. Epub 2011 Mar 3. Review.

PMID:
21376485
20.

Role of cannabinoids in multiple sclerosis.

Zajicek JP, Apostu VI.

CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. Review.

PMID:
21323391
21.

Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis.

Cano SJ, Barrett LE, Zajicek JP, Hobart JC.

Mult Scler. 2011 Feb;17(2):214-22. doi: 10.1177/1352458510385269. Epub 2010 Oct 14.

PMID:
20947530
22.
23.

Melanoma following treatment with alemtuzumab for multiple sclerosis.

Pace AA, Zajicek JP.

Eur J Neurol. 2009 Apr;16(4):e70-1. doi: 10.1111/j.1468-1331.2009.02552.x. No abstract available.

PMID:
19222552
24.

Therapeutic potential of cannabis in pain medicine.

Hosking RD, Zajicek JP.

Br J Anaesth. 2008 Jul;101(1):59-68. doi: 10.1093/bja/aen119. Epub 2008 May 29. Review.

25.

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, Zajicek JP, Scolding NJ, Robertson NP.

J Neurol. 2008 Feb;255(2):231-8. doi: 10.1007/s00415-008-0696-y. Epub 2008 Feb 20.

PMID:
18283404
26.

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations.

Hobart JC, Cano SJ, Zajicek JP, Thompson AJ.

Lancet Neurol. 2007 Dec;6(12):1094-105. Review. Erratum in: Lancet Neurol. 2008 Jan;7(1):25.

PMID:
18031706
27.

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1664-9.

28.

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ, Zajicek JP.

Brain. 2006 Jan;129(Pt 1):224-34. Epub 2005 Nov 9.

PMID:
16280352
29.

Muscle cramps and weakness secondary to graft versus host disease fasciitis.

Carroll CB, Hilton DA, Hamon M, Zajicek JP.

Eur J Neurol. 2005 Apr;12(4):320-2. No abstract available.

PMID:
15804251
30.

Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.

Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP.

Neurology. 2004 Oct 12;63(7):1245-50.

PMID:
15477546
31.

The 'harlequin' sign in association with multiple sclerosis.

Carroll CB, Zajicek JP.

J Neurol. 2004 Sep;251(9):1145-6. No abstract available.

PMID:
15372263
32.

The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria.

Fox CM, Bensa S, Bray I, Zajicek JP.

J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):56-60.

33.

Immunosuppressive treatments in MS--side effects from azathioprine.

Craner MJ, Zajicek JP.

J Neurol. 2001 Jul;248(7):625-6. No abstract available.

PMID:
11518009
34.

Neurosarcoidosis.

Zajicek JP.

Curr Opin Neurol. 2000 Jun;13(3):323-5. Review.

PMID:
10871259
35.

Central nervous system sarcoidosis--diagnosis and management.

Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D.

QJM. 1999 Feb;92(2):103-17.

PMID:
10209662
36.

Cerebral vasculitis--recognition, diagnosis and management.

Scolding NJ, Jayne DR, Zajicek JP, Meyer PA, Wraight EP, Lockwood CM.

QJM. 1997 Jan;90(1):61-73.

PMID:
9093590
37.

The pathogenesis of demyelinating disease.

Scolding NJ, Zajicek JP, Wood N, Compston DA.

Prog Neurobiol. 1994 Jun;43(2):143-73. Review. No abstract available.

PMID:
7972853
38.

Supplemental Content

Loading ...
Support Center